Repurposed drug – Page 7 – Communicable Diseases Research

Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective

성인의 COVID-19 치료를 위한 회복기 혈장 수혈: 글로벌 관점

Review

Published on 2021-05-072022-09-10
Journal: Viruses [Category] SARS, 변종,

Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics

SARS-CoV-2 주요 프로테아제에서 글루타민 189 유연성의 중요성: ChEMBL 데이터베이스 및 분자 역학의 인실리코 가상 스크리닝에서 얻은 교훈

Article

Published on 2021-05-012022-09-11
Journal: European journal of pharmaceutical sciences : offi [Category] SARS, 치료제,

[키워드] approved caused ChEMBL ChEMBL database Clinical management complexes Compound COVID-19 database evaluated filtered finger GLN189 global pandemic Glutamine Importance in silico include infected patient infected patients infection control inhibitor inhibitory activity lesson MD simulation mechanical ventilator molecular molecular docking molecular dynamics Molecular dynamics (MD) outbreak oxygen performed pharmacological pharmacophore Pharmacophore elucidation pharmacophores plasticity protease Protein target Repurposed drug Repurposed drugs S-protein SARS-CoV-2 SARS-CoV-2 main protease social distancing supplemental oxygen Support supportive care targets the SARS-CoV-2 therapeutic efficacy training set treating COVID-19 US-FDA Virtual screening were used WHO guideline
[DOI] 10.1016/j.ejps.2021.105744 PMC 바로가기 [Article Type] Article

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial

하이드록시클로로퀸 또는 로피나비르 및 리토나비르를 사용한 조기 치료가 COVID-19 환자의 입원 위험에 미치는 영향 The TOGETHER 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-04-222022-08-13
Journal: JAMA Network Open [Category] MERS, 임상, 진단, 치료제,

[키워드] Administered adverse events age all-cause hospitalization Analysis analyzed assigned benefit Brazil clinical clinical outcomes clinical trial ClinicalTrials.gov Identifier: NCT04403100 conducted country Course COVID-19 COVID-19 pandemic COVID-19 treatment guideline COVID-19 treatment guidelines Cox proportional hazard Cox proportional hazards model data safety monitoring board death determine diagnosed early symptomatic COVID-19 Effect effective Efficacy enrolled Enrollment expedient clinical trial expedient clinical trials fatality finding followed by futility group hazard ratio high-risk patient High-risk patients Hospitalization Hydroxychloroquine hydroxychloroquine group Importance Interim analyses interim analysis Intervention intervention group large-scale outpatient clinical trials Loading dose Lopinavir Lopinavir-ritonavir measure monitoring board no significant difference no significant differences not significantly different objective Odds ratio Outpatient outpatients pandemic participant Participants Patient patients patients hospitalized patients treated Placebo placebo group Point Prevent Primary outcome Primary outcomes proportion proportional hazards model randomization Randomized randomized clinical trial Randomly recorded reduce reducing Registration Relevance Repurposed drug Repurposed drugs respiratory respiratory symptom respiratory symptoms Result Ritonavir Sample size SARS-COV-2 infection secondary outcome self-identified as mixed-race setting statistical analysis symptom resolution symptomatic adult symptomatic adults the median the placebo group Treatment Trial Viral viral clearance was performed with COVID-19 women
[DOI] 10.1001/jamanetworkopen.2021.6468 PMC 바로가기 [Article Type] Randomized Controlled Trial

Repositioned Drugs for COVID-19—the Impact on Multiple Organs

Covid-19

Published on 2021-04-212022-10-29
Journal: Sn Comprehensive Clinical Medicine [Category] COVID-19,

SARS-CoV-2 M pro : A Potential Target for Peptidomimetics and Small-Molecule Inhibitors

SARS-CoV-2 M pro : 펩티드모방체 및 소분자 억제제의 잠재적 표적

Review

Published on 2021-04-192022-09-10
Journal: Biomolecules [Category] MERS, SARS, 변종, 신약개발, 치료제,

[키워드] Administered Analysis approved Candidates catalytic activity caused clinical complication compounds coronavirus COVID-19 COVID-19 pandemic cysteine cysteine protease debate drug drugs Ebola effective vaccine Efficacy and safety evaluated event FDA HCV Health Impact Infection inhibitor inhibitors interactions interruption Intervention limitation M pro mutate New coronavirus new coronavirus SARS-CoV-2 offer parasite peptidomimetics Potential Prevent priority protease protease inhibitors recommendation Remdesivir Replication Repurposed drug Repurposed drugs repurposing responsible SARS-CoV-2 SARS-CoV-2 M^pro SARS-CoV-2 variant SARS-CoV-2 variants social distancing Spread target Treatment treatment of COVID-19 treatment of HIV Viral viral infection viral replication while WHO’ world population
[DOI] 10.3390/biom11040607 PMC 바로가기 [Article Type] Review

iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility

Research Article

Published on 2021-04-062022-10-31
Journal: FEBS Open Bio [Category] COVID-19, SARS,

[키워드] antiviral activity Antiviral effect blocked cells Combination Compound conducted demonstrated drug drugs Ebola virus Efficacy estrogen receptor evaluated exhibited genomic RNA host cell host cells Huh7 cell Human Human immune system human iPSC identify Infection infections inhibitory effect local outbreak modulate modulating mutated Mutation Pandemics Paramyxoviridae pathogenic pioglitazone pluripotent stem cell PPARγ PPARγ public health Repurposed drug RNA virus RNA viruses SARS‐CoV‐2 SARS‐CoV‐2 Sendai virus SERMs susceptibility synergistic therapeutic therapeutic potential threat Vaccine Vero E6 cell VERO E6 cells Viral diseases virus viruses while
[DOI] 10.1002/2211-5463.13153 PMC 바로가기 [Article Type] Research Article

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Review

Published on 2021-04-052022-10-28
Journal: Vaccines [Category] COVID-19,

Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics

Perspective

Published on 2021-04-052022-10-28
Journal: Pharmaceutics [Category] COVID-19,

Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients

Randomized Controlled Trial

Published on 2021-04-012022-10-05
Journal: Phytomedicine : international journal of phytother [Category] Coronavirus, 신약개발, 임상, 치료법,

[키워드] absolute reduction Administered adverse effect Alpha Anu Anu taila approach asymptomatic patient Ayurveda blinded C-reactive protein clinical clinical trial complementary conducted COVID-19 COVID-19 positive patient Department dissemination double-blind Efficacy evaluate faster Fold change groups help IL-6 include India Infection inflammation marker interleukin-6 less Medical Science Medicine nasal nasopharyngeal Necrosis nostril Ocimum Ocimum sanctum oropharyngeal swab Patient per day pilot clinical trial Placebo placebo-controlled randomization Randomized Randomized placebo-controlled pilot clinical trial reduce Registered Registration Repurposed drug risk RT-qPCR test SARS-COV-2 infection sensitivity Serum level severity Specific study participant suggested Swasari Ras Tablet the patient the placebo group Tinospora cordifolia TNF-α Treatment treatment for COVID-19 treatment group unmet need Viral load virological clearance was used weighed were given while with COVID-19 Withania somnifera yielding
[DOI] 10.1016/j.phymed.2021.153494 PMC 바로가기 [Article Type] Randomized Controlled Trial

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies

재활용된 COVID-19 약물과 폐암 약물 요법의 잠재적 약물 상호 작용

Review

Published on 2021-04-012022-08-31
Journal: Archives of medical research [Category] MERS, SARS, 신약개발, 치료제,

[키워드] adverse outcomes anti-cancer treatment Azithromycin cancer patient Care ceftriaxone Chemotherapy Chloroquine Comorbidity Complication concomitant treatment concomitant treatments COVID-19 COVID-19 infection COVID-19 pandemic Dexamethasone dissemination drug Drug interactions drug-drug interaction Drug-drug interactions Famotidine Favipiravir Healthcare professional healthcare professionals history of smoking Hydroxychloroquine identification identify Immunosuppression information kinase inhibitors Lopinavir Lopinavir/ritonavir lung cancer lung cancer patient lung cancer patients malignancy management medication medications occur oseltamivir outcome Patient pharmacotherapy Potential Prophylactic proportion QT prolongation rationale receiving recent Remdesivir reported Reporting Repurposed drug ribavirin risk risk factor Ritonavir sarilumab severity smoking Tocilizumab tyrosine tyrosine kinase inhibitors umifenovir with COVID-19
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review